(Q22252627)

13 December 2019

immunoglobulin therapy

1 reference

13 December 2019

1

Pieter A van Doorn

Pieter A.

van Doorn

1 reference

7 February 2023

6

Bart C Jacobs

Bart C.

Jacobs

1 reference

7 February 2023

Krista Kuitwaard

2

Krista

Kuitwaard

1 reference

7 February 2023

Christa Walgaard

series ordinal

3

author given names

Christa

author last names

Walgaard

1 reference

7 February 2023

Rinske van Koningsveld

series ordinal

4

author given names

Rinske

author last names

van Koningsveld

1 reference

7 February 2023

Liselotte Ruts

series ordinal

5

author given names

Liselotte

author last names

Ruts

1 reference

Journal of Clinical Immunology

7 February 2023

language of work or name

English

0 references

publication date

January 2010

0 references

May 2010

0 references

1 May 2010

5 references

25 April 2019

30 June 2019

27 November 2019

13 December 2019

11 February 2023

5 references

25 April 2019

30 June 2019

27 November 2019

13 December 2019

11 February 2023

30

0 references

30 Suppl 1

0 references

issue

1

0 references

S1

0 references

page(s)

74-9

0 references

S74-8

0 references

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

1 reference

Europe PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

11 February 2023

cites work

Guillain-Barré syndrome

2 references

Immunotherapy for Guillain-Barre syndrome: a systematic review

27 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

Intravenous immunoglobulin for Guillain-Barré syndrome

27 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome

27 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

Assessment of current diagnostic criteria for Guillain-Barré syndrome

27 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

A clinical prognostic scoring system for Guillain-Barré syndrome

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

The immunobiology of Guillain-Barré syndromes

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

The spectrum of antecedent infections in Guillain-Barre syndrome: A case-control study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

Plasma exchange for Guillain-Barré syndrome.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2883091

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

29 November 2018

1 reference

12 December 2020

Infections and course of disease in mild forms of Guillain-Barré syndrome

1 reference

12 December 2020

Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome

1 reference

12 December 2020

Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

1 reference

12 December 2020

Treatment for Guillain-Barré syndrome

1 reference

12 December 2020

Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome

1 reference

12 December 2020

10.1007/S10875-010-9407-4

Identifiers

DOI

0 references